New drug combo targets Hard-to-Treat stomach cancers
NCT ID NCT07689292
First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 participants and measures safety, tumor shrinkage, and how long the cancer is kept under control. The goal is to see if this drug pair can offer a new option when standard treatments stop working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (Sac-TMT) plus fruquintinib
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced gastric or gastroesophageal junction cancer.
- What could go wrong
- This is an early-phase trial with only 45 participants, so results may not apply to all patients. The combination may cause side effects and may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug attack slow down stomach cancer?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a less extensive stomach surgery preserve appetite better?
- New drug combo aims to outperform immunotherapy in Hard-to-Treat stomach cancer
- Breath of life: new test could sniff out gut cancers before they spread
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers